Print this page

[53] Information by division/country and region 

XLS

Information by division

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Merck Serono

Consumer Health

Performance Materials

€ million

2012

2011

2012

2011

2012

2011

1

Previous year’s figures have been adjusted, see Note [5]

2

According to the cash flow statement

Sales

5,995.8

5,564.4

472.6

494.2

1,674.2

1,464.7

Royalty, license and commission income

409.4

355.6

2.6

2.0

1.4

2.7

Total revenues

6,405.2

5,920.0

475.2

496.2

1,675.6

1,467.4

Gross margin

5,212.1

4,891.71

316.7

339.01

959.1

875.31

Marketing and selling expenses

–1,370.8

–1,412.01

–218.5

–232.81

–142.8

–132.41

Royalty, license and commission expenses

–561.6

–478.5

–1.0

–3.7

–1.5

–2.3

Administration expenses

–250.2

–253.41

–23.1

–23.51

–35.2

–33.11

Other operating expenses and income

–674.9

–382.01

–46.2

–5.1

–39.2

127.41

Research and development

–1,187.3

–1,224.51

–19.4

–22.81

–137.4

–132.81

Operating result (EBIT)

508.3

342.21

4.3

46.91

598.5

691.01

Depreciation and amortization

881.1

840.8

11.5

11.3

114.1

102.5

Impairment losses

51.2

344.4

10.7

0.3

12.1

9.5

Other

–0.5

–1.3

–1.9

EBITDA

1,440.6

1,526.91

26.5

58.51

723.4

801.11

One-time items

344.7

42.1

37.0

7.3

–118.4

EBITDA pre one-time items (Segment result)

1,785.3

1,569.0

63.5

58.5

730.7

682.7

EBITDA margin pre one-time items (in % of sales)

29.8

28.2

13.4

11.8

43.6

46.6

Net operating assets

8,020.6

9,207.2

283.8

321.1

1,187.7

1,331.0

Segment liabilities

–1,349.8

–1,163.6

–76.5

–80.7

–147.1

–131.7

Investments in property, plant and equipment2

146.9

197.0

4.0

5.2

55.7

64.1

Investments in intangible assets2

88.7

53.0

0.4

6.2

28.6

2.7

Net cash flows from operating activities

2,216.3

1,386.91

72.3

49.41

875.4

573.81

Net cash flows from investing activities

–197.5

101.3

–2.3

–8.8

–70.8

128.6

Free cash flow

2,018.8

1,488.21

70.0

40.61

804.6

702.41

Business free cash flow

1,840.9

1,440.4

85.5

48.2

786.9

572.3

Free cash flow margin (in % of sales)

33.7

26.7

14.8

8.2

48.1

48.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Merck Millipore

Corporate and Other

Group

€ million

2012

2011

2012

2011

2012

2011

Sales

2,598.2

2,382.6

10,740.8

9,905.9

Royalty, license and commission income

18.7

10.2

432.1

370.5

Total revenues

2,616.9

2,392.8

11,172.9

10,276.4

Gross margin

1,531.1

1,389.61

–3.8

–4.81

8,015.2

7,490.81

Marketing and selling expenses

–675.7

–606.01

–3.0

–2.51

–2,410.8

–2,385.71

Royalty, license and commission expenses

–15.7

–16.0

–579.8

–500.5

Administration expenses

–113.5

–104.11

–130.2

–121.51

–552.2

–535.61

Other operating expenses and income

–122.9

–103.01

–243.3

–54.51

–1,126.5

–417.21

Research and development

–166.1

–133.41

–1.1

–0.51

–1,511.3

–1,514.01

Operating result (EBIT)

233.2

235.41

–380.7

–183.41

963.6

1,132.11

Depreciation and amortization

305.0

283.7

7.6

5.4

1,319.3

1,243.7

Impairment losses

4.2

1.8

0.5

78.7

356.0

Other

1.5

–0.1

–1.4

–0.9

EBITDA

542.4

522.41

–372.7

–178.01

2,360.2

2,730.91

One-time items

53.5

38.7

162.2

30.5

604.7

–7.1

EBITDA pre one-time items (Segment result)

595.9

561.1

–210.5

–147.5

2,964.9

2,723.8

EBITDA margin pre one-time items (in % of sales)

22.9

23.6

27.6

27.5

Net operating assets

6,328.9

6,608.6

25.1

–1.3

15,846.1

17,466.6

Segment liabilities

–383.1

–335.4

–33.7

–22.9

–1,990.2

–1,734.3

Investments in property, plant and equipment2

113.2

99.7

9.3

0.3

329.1

366.3

Investments in intangible assets2

10.0

12.0

16.5

5.8

144.2

79.7

Net cash flows from operating activities

639.7

413.41

–1,331.5

–1,152.31

2,472.2

1,271.2

Net cash flows from investing activities

–137.4

–263.3

–749.9

–853.8

–1,157.9

–896.0

Free cash flow

502.2

150.01

–1,355.7

–944.81

2,039.9

1,436.4

Business free cash flow

492.8

352.3

–236.8

–151.3

2,969.3

2,261.9

Free cash flow margin (in % of sales)

19.3

6.3

19.0

14.5

XLS

Information by country and region

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe

thereof Germany

thereof France

€ million

2012

2011

2012

2011

2012

2011

1

Previous year’s figures have been adjusted, see Note [5]

Sales by customer location

3,942.7

3,959.0

801.5

825.8

696.0

731.2

Sales by company location

4,379.9

4,362.3

1,452.9

1,394.5

814.9

853.6

Total revenues

4,677.0

4,630.6

1,472.7

1,430.7

822.0

862.6

Intangible assets

8,293.4

8,920.3

344.9

226.8

302.1

325.7

Property, plant and equipment

2,344.3

2,469.3

996.4

1,070.7

173.9

152.6

Research and development

–1,344.1

–1,375.11

–791.8

–674.81

–56.0

–50.0

Number of employees

20,777

21,830

10,788

10,900

2,950

3,002

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

thereof Switzerland

North America

thereof USA

€ million

2012

2011

2012

2011

2012

2011

Sales by customer location

141.6

139.0

2,128.3

1,789.1

1,965.0

1,641.9

Sales by company location

174.2

168.0

2,121.4

1,781.2

1,979.0

1,651.9

Total revenues

438.4

382.3

2,122.1

1,781.9

1,979.7

1,652.6

Intangible assets

5,343.0

5,984.1

2,462.1

2,599.6

2,461.6

2,598.9

Property, plant and equipment

795.2

855.5

359.6

366.0

358.3

364.5

Research and development

–462.1

–609.2

–114.5

–95.2

–113.3

–92.4

Number of employees

1,926

2,323

4,848

4,962

4,688

4,793

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Emerging Markets

Rest of World

Group

€ million

2012

2011

2012

2011

2012

2011

Sales by customer location

3,712.2

3,283.9

957.6

873.9

10,740.8

9,905.9

Sales by company location

3,408.4

3,001.4

831.1

761.0

10,740.8

9,905.9

Total revenues

3,542.7

3,103.0

831.1

760.9

11,172.9

10,276.4

Intangible assets

141.3

184.0

47.7

60.4

10,944.5

11,764.3

Property, plant and equipment

163.7

176.8

86.0

101.3

2,953.6

3,113.4

Research and development

–28.6

–27.1

–24.1

–16.6

–1,511.3

–1,514.01

Number of employees

11,642

12,229

1,580

1,655

38,847

40,676

© Merck KGaA, Darmstadt, Germany, Last Update 2013/03/07